Navigation Links
InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
Date:1/8/2009

LOS ALTOS, Calif., Jan. 8 /PRNewswire/ -- InteKrin Therapeutics, Inc., will present at the 27th Annual JP Morgan Global Healthcare Conference at 9:00 a.m. Pacific Time on Tuesday, January 13, 2009, to be held at the Westin St. Francis in San Francisco, California. InteKrin Therapeutics' President and CEO Denny Lanfear will present at the conference.

About InteKrin (http://www.InteKrin.com):

InteKrin Therapeutics is a privately-held clinical stage biopharmaceutical company focused on the development and commercialization of novel drugs for the treatment of diabetes, obesity and metabolic disease. The company's lead program is INT131, a late-stage non-TZD SPPARM (Selective Peroxisome Proliferator-Activated Receptor Modulator). INT131 is the result of an extensive molecular design effort to address the problematic safety concerns of TZD full PPAR agonists Actos(R) (pioglitazone) and Avandia(R) (rosiglitazone), which while efficacious are associated with weight gain, edema, congestive heart failure and bone fracture. Unlike TZDs, INT131 was specifically selected for its ability to separate powerful PPAR anti-diabetic efficacy from these serious TZD side effects.

INT131 is a next-generation insulin sensitizer that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Treating and improving insulin sensitivity in diabetic patients by activating PPAR-gamma is an important therapeutic tool for physicians, providing powerful glucose control and durability of effect. As a SPPARM, INT131 selectively modulates PPAR-gamma, and is ideally positioned to safely reduce insulin resistance, addressing an important unmet medical need.

InteKrin expects to complete enrollment of its 360 patient, 24-week, placebo-controlled Phase 2b study of INT131 at four doses compared to 45mg Actos in
'/>"/>

SOURCE InteKrin Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
2. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
3. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
4. Horizon Therapeutics Announces Senior Management Appointments
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
6. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
7. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
8. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
9. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
10. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
11. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... Albany, New York (PRWEB) July 12, 2014 ... market analysis for various reagents used in ... biotechnology is driving the life science reagents ... this study include manufacturers and providers of ... Science Reagents Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . ...
(Date:7/11/2014)... , July 11, 2014 ... to announce the appointment of John P. Donoghue ... Biotech   in  Geneva . The ... Campus Biotech in Geneva , has ... recognised neuroscientists. John P. Donoghue , founder of ...
(Date:7/10/2014)... 2014 Product and process impurities ... abundance and are often “lost in the noise,” ... Join presenters Dr. Rowel Tobias, Senior Scientist, Protein ... Head of Quality at Nanotherapeutics, Inc., to lear ... speed detection and quantitation while achieving the required ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... platform offers multiple diagnostic modalities on a single ... to ... physicians and administrators, SAN DIEGO, March 28 ... of intravascular,ultrasound (IVUS), functional measurement (FM) and Optical Coherence,Tomography (OCT) ...
... /Xinhua-PRNewswire/ -- Tiens Biotech Group (USA),Inc. ("the Company" or ... financial results for the fourth quarter and twelve months ... of 2007 was $13.3 million compared to,$16.6 million for ... the fourth quarter of 2007 was $3.9 million, or ...
... -. Actavis Group, the,international generic pharmaceuticals company, ... approvals from the U.S. Food & Drug ... Distribution,of the products will commence immediately., ... strength, are the generic equivalent of Wellbutrin ...
Cached Biology Technology:Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR 2Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR 3Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR 4Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR 5Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 2Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 3Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 4Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 5Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 6Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 7Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 8Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 9Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 10Actavis Receives Approval of Generic Wellbutrin SR(R) and Zyban(R) Tablets in the U.S. 2
(Date:7/11/2014)... evidence that under the normal circumstances, astrocytes ... maintain neuronal environment, and exhibit therapeutic and ... disease. Previous studies have found that nerve ... chemical induction have reduced viability, which produces ... Xiaodong Yuan, Kailuan General Hospital, Hebei United ...
(Date:7/11/2014)... , July 11, 2014 Research ... "International Biometrics Technology Market - Industry Analysis Size ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... and crimes has created a need for high level ... used for personnel authentication such as username and passwords, ...
(Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2Blame it on the astrocytes 2
... has made new links between 29 regions of the genome ... disease (IBD). The new findings increase the total number of ... to 99. The results point to several biological processes, ... the intestinal wall, which are likely to play an important ...
... With millions of people warding off winter,s chill with ... flags about the potential health effects of the smoke ... American Chemical Society,s (ACS,) journal, Chemical Research in ... the lungs from wood smoke may have several adverse ...
... they seem when it comes to fishsomething scientists at the ... Using modern genetic analysis, combined with traditional examination of morphology, ... three species of blenny in the genus Starksia ... in the scientific journal ZooKeys , Feb. 3. ...
Cached Biology News:Research links 29 genome regions with common form of inflammatory bowel disease 2Research links 29 genome regions with common form of inflammatory bowel disease 3Smithsonian scientists discover 7 new species of fish 2
The 50 ml Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: four 50 ml tubes. ,Magnets: Neodymium rare earth permanent magnets....
ChIP-GLAS kit for H10K-B microarray chips. Contains ChIP kit, GLAS kit, and hybridization kit. Additional reagents are required. Please see manual for details. Contains sufficient reagent for 20 reac...
...
...
Biology Products: